Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Journal of Psychopharmacology
S L de HaasJ M A van Gerven

Abstract

The use of non-selective gamma-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered by unfavourable side effects. some of these may be associated with binding properties to certain subtypes of the GABA(A) receptor that are unnecessary for therapeutic effects. MK-0343 was designed to be a less sedating anxiolytic, based on reduced efficacy at the alpha1 subtype and significant efficacy at alpha2 and alpha3 subtypes of the GABA(A) receptor. This paper is a double-blind, four-way cross-over (n = 12) study to investigate the effects of MK-0343 (0.25 and 0.75 mg) in comparison to placebo and an anxiolytic dose (2 mg) of the non-selective agonist lorazepam. Effects were measured by eye movements, body sway, Visual Analogue scales (VAS) and memory tests. Lorazepam impaired saccadic peak velocity (SPV), VAs alertness scores, postural stability and memory and increased saccadic latency and inaccuracy. MK-0343 0.75 mg was equipotent with lorazepam as indicated by SPV (-42.4 deg/s), saccadic latency (0.02 s) and VAS alertness scores (1.50 ln mm), while effects on memory and postural stability were smaller. MK-0343 0.25 mg only affected postural stability to a si...Continue Reading

References

Oct 1, 1992·Clinical Pharmacology and Therapeutics·A L van SteveninckA F Cohen
Jul 1, 1985·British Journal of Clinical Pharmacology·A Patat, P Foulhoux
Jan 1, 1993·Psychopharmacology·A L van SteveninckA F Cohen
Jun 1, 1996·British Journal of Clinical Pharmacology·A L van SteveninckA F Cohen
May 20, 1998·Pharmacology, Biochemistry, and Behavior·M J MattilaT Seppälä
Mar 5, 1999·Journal of Psychopharmacology·S E Buffett-JerrottM D Teehan
Nov 7, 2000·Perceptual and Motor Skills·R E NelsonJ H Baños
Apr 3, 2001·Trends in Pharmacological Sciences·U RudolphH Möhler
May 17, 2001·Proceedings of the National Academy of Sciences of the United States of America·I ToblerU Rudolph
Nov 20, 2001·Current Opinion in Pharmacology·H MöhlerU Rudolph
Jan 22, 2003·British Journal of Clinical Pharmacology·S J de VisserJ M A van Gerven
Jul 23, 2003·Current Drug Targets. CNS and Neurological Disorders·John R Atack
Dec 3, 2003·Nature Medicine·Timothy B C JohnstoneKelvin W Gee
Oct 16, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marie Izaute, Elisabeth Bacon
Jan 19, 2005·British Journal of Pharmacology·John R AtackGerard R Dawson
May 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·A LippaP Skolnick
Nov 18, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Rebecca DiasDavid S Reynolds
Dec 20, 2005·Current Opinion in Pharmacology·Paul J Whiting

❮ Previous
Next ❯

Citations

Mar 5, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Hanns Ulrich ZeilhoferKatharina Hösl
Nov 27, 2009·The Journal of Pharmacology and Experimental Therapeutics·Kelvin W GeeEdward R Whittemore
Mar 1, 2012·Advances in Pharmacological Sciences·Xia ChenJoop van Gerven
Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Uwe Rudolph, Hanns Möhler
Sep 6, 2013·Drugs & Aging·Maartje H de GrootClaudine J C Lamoth
Aug 23, 2011·Annual Review of Pharmacology and Toxicology·Hanns Ulrich ZeilhoferGonzalo E Yevenes
Jan 6, 2015·Expert Opinion on Investigational Drugs·Roberto Mandrioli, Laura Mercolini
Jul 7, 2009·Drug Discovery Today·Charlotte D'HulstR Frank Kooy
Feb 10, 2010·Journal of Psychopharmacology·Marieke Liem-MoolenaarJoop M A van Gerven
Aug 30, 2008·Journal of Psychopharmacology·S Wilson, D Nutt
May 23, 2018·Journal of Psychopharmacology·Ulrich EttingerAdam M Perkins
Jun 12, 2009·British Journal of Hospital Medicine·Sue Wilson
Oct 31, 2019·Molecular Genetics & Genomic Medicine·Yanzi MengGuijun Qin
Mar 24, 2011·Future Medicinal Chemistry·Chris R J CarterSusan M J Dunn
Feb 11, 2011·British Journal of Clinical Pharmacology·Marieke Liem-MoolenaarJoop M A van Gerven
Dec 7, 2016·British Journal of Clinical Pharmacology·Xia ChenJoop van Gerven
Nov 8, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·Priska KaufmannJasper Dingemanse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.